Clinical trials: Hemostasis
CLL, Multiple Myeloma
The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19
The corona pandemic is a continuing global challenge due to Corona Virus 2019 (COVID-19). The purpose of the study is to evaluate the capability of Haemato-oncology patients to generate antibodies against COVID-19 after infection…
- Conditions
- CLL, Multiple Myeloma, Lymphoma
- Trial name
- NCT04746092
- Where
- Israel
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Surgery
Effect of Prostacyclin on Haemostasis in Abdominal Surgery
The purpose of this study is to investigate the effect of continuous perioperative infusion of prostacyclin on haemostasis and endothelial functionality in patients undergoing major abdominal surgery.
- Trial name
- NCT01528943
- Testing
- Prostacycline, Isotonic saline
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple Myeloma
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a…
- Trial name
- NCT02332850
- Testing
- Isatuximab, Carfilzomib, Dexamethasone
- Where
- 6 sites in United States, Canada
- Volunteers
- 83 people
- Sponsor
- Thomas Martin, MD
Stage II Multiple Myeloma, Stage III Multiple Myeloma
Vaccine Therapy in Treating Patients With Multiple Myeloma
RATIONALE: Vaccines made from a person's tumor cells may make the body build an immune response and kill their tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Trial name
- NCT00019097
- Testing
- autologous tumor cell vaccine, keyhole limpet hemocyanin, melphalan
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Newly Diagnosed
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in…
- Trial name
- CAREMM-005 (NCT07106710)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Pseudoxanthoma Elasticum
What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum
The investigators hypothesize is that in PXE patients, low grade chronic inflammation could preceed the molecular and the clinical calcification process.
- Trial name
- GOCAPXE (NCT03070860)
- Testing
- PET scan 18-FDG and 18-NAF
- Where
- France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Angers
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory).
- Trial name
- NCT01415882
- Testing
- Cyclophosphamide, Daratumumab, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 165 people
- Sponsor
- Mayo Clinic
Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
This pilot phase II trial studies how well high dose cyclophosphamide, tacrolimus, and mycophenolate mofetil work in preventing graft versus host disease in patients with hematological malignancies undergoing myeloablative or…
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03128359
- Testing
- Busulfan, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
- Trial name
- MM (NCT04960579)
- Testing
- P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate
- Where
- 23 sites in United States
- Volunteers
- 275 people
- Sponsor
- Poseida Therapeutics, Inc.
Multiple Myeloma
sdAb-based TRNT of Multiple Myeloma: a Feasibility Study
This study aims to show that antiidiotypic sdAb are a new, sensitive, specific and non-invasive tool for imaging and therapeutic purposes and provides a rationale for their clinical evaluation as a personalized treatment option…
- Trial name
- MUM (NCT03956615)
- Testing
- Blood sampling and bone marrow analysis
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Universitair Ziekenhuis Brussel
Relapsed/Refractory Multiple Myeloma
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evaluate the safety, tolerability, PK profile, immunogenicity and efficacy of LBL-034.
- Trial name
- NCT06049290
- Testing
- LBL-034 for Injection
- Where
- 21 sites in China
- Volunteers
- 342 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Ovarian Cyst Benign
PReservation Study of Ovarian Function And Hemostasis, and Its Safety of Surgiguard@ During Laparoscopic Ovarian Cystectomy
The purpose of this study is to compare hemostasis, ovarian function preservation effect, and safety about intraoperative bleeding with SurgiGuard@ in women who underwent laparoscopic unilateral ovarian cystectomy
- Trial name
- PRAHA (NCT03374397)
- Testing
- Surgiguard
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Seoul National University Hospital
Leukemia, Lymphoma
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002989
- Testing
- busulfan, cyclophosphamide, idarubicin
- Where
- 9 sites in Belgium, France and 3 more
- Volunteers
- 207 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Multiple Myeloma
Risk-adapted Therapeutic Strategy in +1q NDMM
This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal…
- Trial name
- NCT07045168
- Testing
- risk-scoring model
- Where
- China
- Volunteers
- 200 people
- Sponsor
- FengYan Jin
Coagulopathy, Cardiopulmonary Bypass
Evaluation of TEG 6S PM® During Cardiopulmonary Bypass to Detect Postoperative Biological Coagulopathy
This is a prospective study to evaluate the predictive value of the TEG 6s platelet mapping® (TEG 6s® PM) performed during cardiopulmonary bypass (CPB) in the prediction of biological coagulopathy (determined by TEG 6S global…
- Conditions
- Coagulopathy, Cardiopulmonary Bypass, Cardiac Surgery
- Trial name
- PREDIPOC (NCT06230640)
- Testing
- In vitro medical diagnostic device TEG6s® Platelet Mapping
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Montpellier
Endobronchial Bleeding, Hemoptysis
The Efficacy of Tranexamic Acid and Adrenaline to Control Endobronchial Bleeding
During bronchoscopy (a procedure using a thin, flexible camera to look inside the airways), doctors sometimes take small tissue samples (biopsies) to diagnose lung conditions. This can cause bleeding in the airway.
- Trial name
- CATER (NCT07759089)
- Testing
- Adrenaline, Tranexamic Acid
- Where
- Pakistan
- Volunteers
- 76 people
- Sponsor
- Sheikh Zayed Federal Postgraduate Medical Institute
MULTIPLE MYELOMA
UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma
To evaluate changes in coagulation (blood clotting) factors and platelet function in multiple myeloma participants undergoing VELCADE treatment for the first time.
- Trial name
- NCT00569868
- Testing
- Velcade
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Multiple Myeloma
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of KQ-2003 CAR-T cells for the treatment of multiple myeloma
- Trial name
- NCT04714827
- Testing
- KQ-2003 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanxi Province Cancer Hospital
Lymphoma, Breast Neoplasms
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
Chemotherapy can often cause anemia in patients with cancer. Anemia is a low number of red blood cells. The symptoms of anemia may include fatigue, dizziness, headache, chest pain, and shortness of breath.
- Conditions
- Lymphoma, Breast Neoplasms, Lung Neoplasms, Multiple Myeloma
- Trial name
- NCT00036023
- Testing
- darbepoetin alfa
- Sponsor
- Amgen
Multiple Myeloma, Solid Tumors
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer.
- Conditions
- Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
- Trial name
- NCT01457417
- Testing
- DKN-01
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Leap Therapeutics, Inc.